{"url_path":"/sec/tak/10-k/2026/item-9","section_key":"item-9","section_title":"Item 9 The Offer and Listing","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1395064/0001395064-26-000177-index.html","accession_number":"0001395064-26-000177","cik":"0001395064","ticker":"TAK","issuer_name":"TAKEDA PHARMACEUTICAL CO LTD","edgar_url":"https://www.sec.gov/Archives/edgar/data/1395064/0001395064-26-000177-index.html","primary_entity_key":"0001395064","primary_entity_name":"TAKEDA PHARMACEUTICAL CO LTD"},"word_count":123,"has_tables":true,"body_markdown":"Item 9. The Offer and Listing\n\nA. Offer and Listing Details\n\nSee “Item 9.C. Markets” of this annual report.\n\nB. Plan of Distribution\n\nNot applicable.\n\nC. Markets\n\nIn Japan, our common stock has been listed since 1949 on the Tokyo Stock Exchange. Our common stock is also listed on the Nagoya Stock Exchange, the Fukuoka Stock Exchange and the Sapporo Securities Exchange. On each of these markets, our common stock trades under the securities identification code “4502.”\n\nADSs, each representing 0.5 shares of our common stock, have been listed on the New York Stock Exchange since 2018 and trade under the symbol “TAK.”\n\nD. Selling Shareholders\n\nNot applicable.\n\nE. Dilution\n\nNot applicable.\n\nF. Expenses of the Issue\n\nNot applicable.\n\n120\n\n[Table of Contents](#i89761be648564855b53fa24df8e6ee90_10)"}